Skip to main content
OpenTrials
Completed

NCT Number: NCT01609634

New Infant Formula Trial in Healthy Term Subjects on Growth, Body Composition, Tolerance and Safety

This study is initiated to investigate the effect of a new infant formula in healthy term subjects on growth, body composition, tolerance and safety.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

Up to 28 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

KK Women's and Children's Hospital, Singapore

Loading trial locations.

About this study

This is a "best after breast design" to measure the effect of this new infant formula in healthy term subjects on growth, body composition, tolerance and safety including immune status, gut microbiota, and early indicators (markers) of disease. These markers will be explored if they could predict the risk of eczema and other allergic disease, and to evaluate if these markers are influenced by early nutrition.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy term infants (gestational age ≥ 37 and ≤ 42 weeks)
  • Age ≤ 28 days
  • Birth weight within normal range for gestational age and sex (3rd to 90th percentile according to applicable growth charts)
  • Head circumference at birth within normal range (3rd to 90th percentile of the chart)
  • Chinese, Malay, or Indian ethnicity
  • Written informed consent from parent(s)
  • Currently reside in Singapore and with the intention to reside in Singapore for at least the next 2 years

Exclusion criteria

for the pregnant women/parents:

  • Pregnant women / mothers who are currently participating or will participate in any other (clinical) study involving investigational or marketed products during pregnancy and/or lactation.
  • Pregnant women / mothers known to suffer from hepatitis B or human immunodeficiency virus (HIV)
  • Pregnant women / mothers known to have other significant medical condition (including during pregnancy) that might interfere with the study or known to affect intra-uterine growth (including, but not limited to: placenta previa, pre-eclampsia, eclampsia, gestational diabetes requiring insulin or oral medication), as per investigator's clinical judgement
  • Incapability of the parents to comply with study protocol or Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements

Exclusion criteria

for the subjects:

  • Infants known to have current or previous illnesses/ conditions or intervention which could interfere with the study (growth), as per investigator's clinical judgement
  • Infants with known congenital diseases or malformations which could interfere with the study (e.g. gastrointestinal malformations, congenital immunodeficiency), as per investigator's clinical judgement
  • Infants who need to be fed with a special diet other than a standard cow's milk-based infant formula
  • Infants who received any other infant formula, except the infant formula given in between birth and the initial breast-feeding (maximum of 3 consecutive days)
  • Infants with any history of or current participation in any other study involving investigational or marketed products.

Treatment and study plan

Test Product

Other

Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®

Control Product 1

Other

Control group 1: Standard infant formula/follow-on formula with added scGOS/lcFOS

Control Product 2

Other

Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.

Primary outcomes

  1. Weight gain per day

    Time frame: 17 weeks

    Weight gain per day from randomisation until 17 weeks of age.

  2. Total weight gain

    Time frame: 12 months

    Total weight gain from birth until 12 months of age

  3. Sum of skin fold thicknesses

    Time frame: 24 months

    Sum of skin fold thicknesses: triceps, biceps, suprailiac, subscapular until 24 months of age in subjects receiving the test product 1, test product 2, or control product.

Secondary outcomes

  1. Recumbent length, head circumference, mid-upper arm circumference, skin folds

    Time frame: 17 weeks

    Recumbent length, head circumference, mid-upper arm circumference, skin folds gain per day for subjects receiving test product 1 or test product 2

  2. Skin-fold thickness

    Time frame: 12 months

    Sum of four Skin-fold thickness: triceps, biceps, subscapular and suprailiac measured until 12 months of age

  3. Weight, length, BMI, head circumference, mid-upper arm circumference, subscapular skinfold, triceps skinfold

    Time frame: 24 months

    Weight, length, BMI, head circumference, mid-upper arm circumference, subscapular skinfold, triceps skinfold measured until 24 months of age

Sponsors and collaborators

Lead sponsor

Danone Asia Pacific Holdings Pte, Ltd.

Industry

Collaborators

  • Nutricia Research

Registry information

Official study title

A Randomised, Controlled, Double-blind Trial to Investigate the Effects of a New Infant Formula in Healthy Term Subjects on Growth, Body Composition, Tolerance and Safety.

Acronym: Venus

Important dates

Study start
2012
Primary completion
2016
Study completion
2019
First posted
Jun 1, 2012
Registry last updated
Oct 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.